Arcutis Biotherapeutics Inc. (ARQT) saw its stock surge 5.08% during Friday's trading session, propelled by the company's impressive quarterly performance and encouraging developments in its drug pipeline.
In its latest earnings report, Arcutis exceeded analyst expectations with a 6% beat on revenue and a narrower-than-expected loss per share. Buoyed by these results, analysts raised their 2025 revenue forecasts for the company by 4.6% to $301.8 million and lowered their projected loss per share by 19% to $0.60.
Adding to the positive sentiment, Arcutis announced that it will present data from two Phase 3 trials of its atopic dermatitis and psoriasis treatments, ZORYVE cream and ZORYVE foam, at the upcoming American Academy of Dermatology annual meeting. The data highlights the products' strong safety and tolerability profiles, as well as improvements in patient-reported outcomes, further bolstering their commercial prospects.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。